Regeneron Archives -

Sanofi and Regeneron should hear from the FDA in the autumn whether it will approve their blockbuster immunology

FDA grants speedy review to Dupixent rare skin disease

https://pharmaphorum.com/news/fda-grants-speedy-review-to-dupixent-rare-skin-disease/

Market Access/ News/ News/ News/ Sales and Marketing

Dupixent claims new territory in eosinophilic oesophagitis

Phil Taylor Dupixent, eosinophilic oesophagitis, Immunology and inflammation, Regeneron, regulatory approval, Sanofi 0 Comment

Sanofi and Regeneron have added another string to the bow of their immunology blockbuster Dupixent with an FDA

Dupixent claims new territory in eosinophilic oesophagitis

https://pharmaphorum.com/news/dupixent-claims-new-territory-in-eosinophilic-oesophagitis/

News/ News/ News/ Oncology/ R&D

Regeneron seeks CheckMate in immuno-oncology play

Phil Taylor CheckMate Pharma, head and neck cancer, immuno-oncology, M&A, melanoma, Oncology, Regeneron, toll-like receptor agonist, vidutolimod 0 Comment

Regeneron has agreed an all-cash deal to acquire CheckMate Pharmaceuticals, adding immune activator vidutolimod to its cancer immunotherapy

Regeneron seeks CheckMate in immuno-oncology play

https://pharmaphorum.com/news/regeneron-seeks-checkmate-in-immuno-oncology-play/

News

FDA says no to AZ’s Fasenra for nasal polyp indication

Phil Taylor AstraZeneca, Dupixent, Fasenra, GlaxoSmithKline, nasal polyps, Nucala, Regeneron, regulatory, Sanofi 0 Comment

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment

FDA says no to AZ’s Fasenra for nasal polyp indication

https://pharmaphorum.com/news/fda-says-no-to-azs-fasenra-for-nasal-polyp-indication/

News/ News/ R&D

Dupixent falls short in phase 3 chronic spontaneous urticaria trial

Phil Taylor chronic spontaneous urticaria, Dupixent, ligelizumab, Novartis, Regeneron, Roche, Sanofi, Xolair 0 Comment

Sanofi and Regeneron have reported disappointing results in a trial of Dupixent in people with chronic spontaneous urticaria

Dupixent falls short in phase 3 chronic spontaneous urticaria trial

https://pharmaphorum.com/news/dupixent-falls-short-in-phase-3-chronic-spontaneous-urticaria-trial/

Genetic testing hopes to speed up drug development in rare eye diseases

News/ News/ R&D

Oxurion reports stronger data for diabetic eye disease drug

Phil Taylor Bayer, diabetic macular oedema, Eylea, ophthalmology, Oxurion, Regeneron 0 Comment

Belgian biotech Oxurion has revealed new data from a phase 2 trial of its plasma kallikrein inhibitor THR-149,

Oxurion reports stronger data for diabetic eye disease drug

https://pharmaphorum.com/news/oxurion-reports-stronger-data-for-diabetic-eye-disease-drug/

News/ News/ R&D

Pfizer sees no way forward for Ionis-partnered vupanorsen

Phil Taylor antisense drugs, cardiovascular, Ionis Pharmaceuticals, Pfizer, Regeneron 0 Comment

Pfizer has called time on its alliance with Ionis for cholesterol-lowering therapy vupanorsen, after a review of phase

Pfizer sees no way forward for Ionis-partnered vupanorsen

https://pharmaphorum.com/news/pfizer-sees-no-way-forward-for-ionis-partnered-vupanorsen/

Market Access/ News/ News

Roche grabs FDA okay for would-be blockbuster eye drug faricimab

Phil Taylor Bayer, DME, Eylea, ophthalmology, Regeneron, regulatory approval, Roche, Susvimo, Vabysmo, wet AMD 0 Comment

The FDA has approved Roche’s much-anticipated faricimab for two major causes of blindness, setting up a market clash

Roche grabs FDA okay for would-be blockbuster eye drug faricimab

https://pharmaphorum.com/news/roche-grabs-fda-okay-for-would-be-blockbuster-eye-drug-faricimab/

News/ News/ Sales and Marketing

FDA bans use of Lilly, Regeneron COVID drugs due to Omicron

Phil Taylor antibody, coronavirus, COVID-19, Eli Lilly, Regeneron, Sales and Marketing 0 Comment

The FDA has limited the use of COVID-19 antibody therapies developed by Eli Lilly and Regeneron, on the

FDA bans use of Lilly, Regeneron COVID drugs due to Omicron

https://pharmaphorum.com/news/fda-bans-use-of-lilly-regeneron-covid-drugs-due-to-omicron/

Trending

Regeneron

Login